# Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

> **NCT05068726** · — · TERMINATED · sponsor: **GE Healthcare** · enrollment: 51 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** 18F Fluoroestradiol Radiopharmaceutical with PET/CT

## Key facts

- **NCT ID:** NCT05068726
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-05
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Sponsor discretion (low recruitment rate)
- **Last updated:** 2024-07-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068726, "Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05068726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*